Hetrombopag + Placebo

Phase 3Completed

2 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Immune Thrombocytopenia

Conditions

Immune Thrombocytopenia

Trial Timeline

Mar 29, 2021 → Jun 17, 2025

NCT ID

NCT04737850

About Hetrombopag + Placebo

Hetrombopag + Placebo is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Immune Thrombocytopenia. The current trial status is completed. This product is registered under clinical trial identifier NCT04737850. Target conditions include Immune Thrombocytopenia.

What happened to similar drugs?

7 of 20 similar drugs in Immune Thrombocytopenia were approved

Approved (7) Terminated (2) Active (13)

✅Lopinavir 400 mg/ritonavir 100 mg + EfavirenzGilead SciencesApproved

✅IgPro10CSLApproved

✅Subcutaneous Immune Globulin (Human) (Hizentra)CSLApproved

✅Methylprednisolone + PrednisoloneBiogenApproved

✅Flebogamma 5% DIFGrifolsApproved

✅Asceniv™ADMA BiologicsApproved

✅BivigamADMA BiologicsApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04737850	Phase 3	Completed	Mar 29, 2021	Jun 17, 2025	Immune Thrombocytopenia
NCT03976882	Phase 3	Completed	Nov 6, 2019	Feb 22, 2023	Chemotherapy-Induced Thrombocytopenia

Competing Products

20 competing products in Immune Thrombocytopenia

See all competitors

Product	Company	Stage	Hype Score
Pirtobrutinib + Placebo	Eli Lilly	Phase 1/2	39
Anti-(integrin beta-3) human monoclonal antibody	Rallybio	Phase 2	17
Satralizumab	Chugai Pharmaceutical	Phase 3	47
Placebo + Lusutrombopag	Shionogi	Phase 2	27
Lusutrombopag	Shionogi	Phase 2	27
Romiplostim	Kyowa Kirin	Phase 1/2	32
AMG 531	Kyowa Kirin	Phase 2/3	38
Romiplostim + Placebo	Kyowa Kirin	Phase 3	40
Romiplostim (AMG-531)	Kyowa Kirin	Phase 2	35
Romiplostim and danazol	Kyowa Kirin	Phase 2	31
Hetrombopag Olamine	Jiangsu Hengrui Medicine	Phase 1	29
SHR0302 quick release tablets + SHR0302 sustained-release tablets	Jiangsu Hengrui Medicine	Phase 1	29
HR19042 Capsule, Tarpeyo®, Budenofalk®	Jiangsu Hengrui Medicine	Phase 1	29
HR19042 Capsules	Jiangsu Hengrui Medicine	Phase 2	35
Herombopag	Jiangsu Hengrui Medicine	Phase 3	36
Zostavax®	Merck	Pre-clinical	18
Raltegravir + Atazanavir	Merck	Pre-clinical	26
Zostavax	Merck	Pre-clinical	26
MK-8723 + Matching Placebo	Merck	Phase 1	29
Eltrombopag (Revolade®) + standard therapy (without eltrombopag): HD-DXM	Novartis	Phase 2	35